We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Courtagen, Astellas Collaborate
News

Courtagen, Astellas Collaborate

Courtagen, Astellas Collaborate
News

Courtagen, Astellas Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Courtagen, Astellas Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Courtagen enters data partnership with Astellas for early stage therapeutic development program to address mitochondrial disease. 

Courtagen Life Sciences, Inc. announced collaboration with Astellas Pharma Inc. Courtagen will utilize its molecular information platform to aid in the development of a predictive model to support early stage therapeutic development for mitochondrial disease. 

“Astellas and Courtagen share a commitment to innovative clinical solutions that address the needs of patients suffering from mitochondrial based disorders.” states Brian McKernan, Chief Executive Officer of Courtagen. “Courtagen was founded on the idea of helping patients suffering from mitochondrial disorders, and now we are able to utilize our unique capability to correlate clinical data with specific genomic alterations and aid in the development of targeted therapeutics.”

Advertisement